-
New Study Points to SX-682 as Strategy to Boost Immunotherapy Effectiveness in Advanced Colorectal Cancer
-AUBURN, WASHINGTON — In collaboration with Syntrix Pharmaceuticals, researchers at the University of Texas MD Anderson Cancer Center revealed that…
0 -
Syntrix Announces First Patient Cohort Dosed in Phase 2 Study of Desmetramadol in Diabetic Neuropathic Pain
-AUBURN, WASHINGTON — Syntrix Pharmaceuticals today announced the initiation of a Phase 2 study evaluating the efficacy and safety of…
-
Syntrix Wins $3.4M NIH Grant to Conduct Phase 1/2 trial of SX-682 in Myelodysplastic Syndrome
-AUBURN, WASHINGTON — Syntrix Pharmaceuticals announced this week that it has been awarded a three-year grant worth $3.4 million from…
-
Desmetramadol featured today in new article by Research Outreach
-Desmetramadol featured today in new article by Research Outreach entitled, “Moving beyond dangerous opioids for pain: Syntrix creates new drug…
-
Syntrix Wins U.S. Patent 10,046,002 – Method for Treating Cancer Using Chemokine Antagonists
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
-
World Health Organization’s INN Approves “Desmetramadol” as Generic Name for Omnitram
-Syntrix today announced that the World Health Organization’s International Nonproprietary Name (INN) group have accepted the proposed generic name “Desmetramadol”…
-
Syntrix Joins National Cancer Institute (NCI) Formulary to Help Expedite Cancer Clinical Trials – Collaboration Will Support Vice President Biden’s Cancer Moonshot Program
-Syntrix today announced their participation in the NCI Formulary, a public-private partnership between the National Cancer Institute (NCI), part of…
-
Syntrix Doses First Subject with Omnitram to Confirm Pain Relief in Patients for Whom Tramadol is Ineffective
-Large patient populations treated with dangerous Schedule II opioids are expected to benefit from Omnitram, a safer alternative without metabolic…
-
Syntrix Wins Three U.S. Patents for Omnitram – 9,717,700; 9,717,701; 9,808,432
-Congratulations to Syntrix scientists on their latest issued patents at the United States Patent and Trademark Office. ‘701 Abstract: Disclosed…
-
Syntrix Wins U.S. Patent 9,707,248 – Use of Thiopyrimidinecarboxamide for Treating Cancer
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
News
Syntrix Pharmaceuticals > News